Association between chronic kidney disease and COVID-19-related mortality in New York

Abstract

Purpose To evaluate mortality risk of CKD patients infected with COVID-19, and assess shared characteristics associated with health disparities in CKD outcome. Methods We extracted the data from a case series of 7624 patients presented at Mount Sinai Health System, in New York for testing between 3/28/2020 and 4/16/2020. De-identified patient data set is being produced by the Scientific Computing department and made available to the Mount Sinai research community at the following website: https ://msdw.mount sinai .org/. Results Of 7624 COVID-19 patients, 7.8% (n = 597) had CKD on hospital admission, and 11.2% (n = 856) died of COVID-19 infection. CKD patients were older, more likely to have diabetes, hypertension, and chronic obstructive pulmonary disease (COPD), were current or former smokers, had a longer time to discharge, and had worse survival compared to non-CKD patients (p < 0.05). COVID-19 mortality rate was significantly higher in CKD patients (23.1% vs 10.2%) with a 1.51 greater odds of dying (95% CI: 1.19-1.90). Controlling for demographic, behavioral, and clinical covariates, the logistic regression analysis showed significant and consistent effects of CKD, older age, male gender, and hypertension with mortality (p < 0.05). Conclusion CKD was a significant independent predictor of COVID-19 mortality, along with older age, male gender, and hypertension. Future research will investigate the effects of COVID-19 on long-term renal function.

COVID-19–Associated Mortality among Kidney Transplant Recipients and Candidates in the United States

“…Additionally, given evidence about the adverse prognostic implications of poor kidney function, patients with functioning kidney transplants might reasonably be expected to fare better than their counterparts who are on dialysis. 19 Differences in the racial/ethnic distribution of the groups who died of COVID-19 compared to other causes of death or deaths in 2019 are particularly startling and are consistent with trends observed in the general population. 20 Black and Hispanic patients together account for 50% of all non-COVID-19 related deaths on the waitlist but were 72% of all COVID-19 related deaths.…”

Impact of asthma on COVID-19 mortality in the United States: Evidence based on a meta-analysis

“…After evaluating and assessing as much as 257 potential studies, 201 studies were removed due to outcome of interest being not available. In the end, what underlay this meta-analysis were eligible fifty-six articles with 426,261 COVID-19 patients [5] , [6] , [7] , [8] , [9] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] . The detail of selection process is shown by a chart flow in Figure 1 .…”

The COVID-19 pandemic — what have urologists learned?

“…AKI in patients with COVID-19 also correlates with patients’ history of chronic kidney disease (CKD) 39 . In a case series of 7,624 patients with COVID-19, the reported mortality was 23.1% in patients with CKD and 10.2% in patients without CKD ( P < 0.001), with odds of mortality 1.51 times higher (95% CI 1.19–1.90) in patients with CKD than in the non-CKD group 40 .…”